PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Brain Research

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.brainres.2016.07.014PMID 27423516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The anti-inflammatory effects of palmitoylethanolamide (PEA) on endotoxin-induced uveitis in rats.

  2015cited by this paper
• Palmitoylethanolamide treatment reduces retinal inflammation in streptozotocin-induced diabetic rats.

  2015cited by this paper
• Co-ultramicronized Palmitoylethanolamide/Luteolin Promotes the Maturation of Oligodendrocyte Precursor Cells

  2015cited by this paper
• Co-ultramicronized Palmitoylethanolamide/Luteolin in the Treatment of Cerebral Ischemia: from Rodent to Man

  2015influential reference
• The Association of Palmitoylethanolamide with Luteolin Decreases Neuroinflammation and Stimulates Autophagy in Parkinson's Disease Model.

  2015cited by this paper
• Roles of fatty acid ethanolamides (FAE) in traumatic and ischemic brain injury.

  2014cited by this paper
• Neuroprotection by association of palmitoylethanolamide with luteolin in experimental Alzheimer's disease models: the control of neuroinflammation.

  2014cited by this paper
• Neuroprotective Effects of Co-UltraPEALut on Secondary Inflammatory Process and Autophagy Involved in Traumatic Brain Injury

  2014influential reference
• Palmitoylethanolamide controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer's disease

  2014cited by this paper
• Anti-Inflammatory and Antipruritic Effects of Luteolin from Perilla (P. frutescens L.) Leaves

  2014cited by this paper
• Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain

  2014cited by this paper
• Targeted acetylation of NF-kappaB/RelA and histones by epigenetic drugs reduces post-ischemic brain injury in mice with an extended therapeutic window.

  2013influential reference
• A new co-ultramicronized composite including palmitoylethanolamide and luteolin to prevent neuroinflammation in spinal cord injury

  2013influential reference
• Glia and Mast Cells as Targets for Palmitoylethanolamide, an Anti-inflammatory and Neuroprotective Lipid Mediator

  2013cited by this paper
• Focal brain inflammation and autism

  2013cited by this paper
• Palmitoylethanolamide and luteolin ameliorate development of arthritis caused by injection of collagen type II in mice

  2013influential reference
• Palmitoylethanolamide in homeostatic and traumatic central nervous system injuries.

  2013influential reference
• Mast cells on the mind: new insights and opportunities.

  2013influential reference
• An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders.

  2013cited by this paper
• Effects of palmitoylethanolamide and luteolin in an animal model of anxiety/depression.

  2013cited by this paper
• New insights in mast cell modulation by palmitoylethanolamide.

  2013cited by this paper
• The role of mast cells in neuroinflammation

  2013influential reference
• Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases

  2013cited by this paper
• Luteolin inhibits mast cell-mediated allergic inflammation.

  2013cited by this paper
• A Case Series of a Luteolin Formulation (Neuroprotek®) in Children with Autism Spectrum Disorders

  2012cited by this paper
• Loss of Environmental Enrichment Increases Vulnerability to Cocaine Addiction

  2012cited by this paper
• Neuroprotective Activities of Palmitoylethanolamide in an Animal Model of Parkinson's Disease

  2012cited by this paper
• Establishment and characterization of mouse bone marrow-derived mast cell hybridomas.

  2012cited by this paper
• Protective Effect of Luteolin in Experimental Ischemic Stroke: Upregulated SOD1, CAT, Bcl-2 and Claudin-5, Down-Regulated MDA and Bax Expression

  2012cited by this paper
• Luteolin downregulates TLR4, TLR5, NF-κB and p-p38MAPK expression, upregulates the p-ERK expression, and protects rat brains against focal ischemia.

  2012cited by this paper
• Reduction of ischemic brain injury by administration of palmitoylethanolamide after transient middle cerebral artery occlusion in rats.

  2012cited by this paper
• Cerebral Mast Cells Mediate Blood-Brain Barrier Disruption in Acute Experimental Ischemic Stroke Through Perivascular Gelatinase Activation

  2011cited by this paper
• Inhibition of cell survival, invasion, tumor growth and histone deacetylase activity by the dietary flavonoid luteolin in human epithelioid cancer cells.

  2011cited by this paper
• Luteolin-7-O-glucoside suppresses leukotriene C(4) production and degranulation by inhibiting the phosphorylation of mitogen activated protein kinases and phospholipase Cγ1 in activated mouse bone marrow-derived mast cells.

  2011cited by this paper
• Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats

  2011cited by this paper
• Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury.

  2011cited by this paper
• Postischemic administration of liposome-encapsulated luteolin prevents against ischemia-reperfusion injury in a rat middle cerebral artery occlusion model.

  2011cited by this paper
• Mast Cells as Early Responders in the Regulation of Acute Blood–Brain Barrier Changes after Cerebral Ischemia and Hemorrhage

  2010cited by this paper
• Intracellular mechanisms of N-acylethanolamine-mediated neuroprotection in a rat model of stroke.

  2010cited by this paper
• Palmitoylethanolamide and other anandamide congeners. Proposed role in the diseased brain.

  2010cited by this paper
• The acetylation of RelA in Lys310 dictates the NF-κB-dependent response in post-ischemic injury

  2010influential reference
• NF‐κB p50/RelA and c‐Rel‐containing dimers: opposite regulators of neuron vulnerability to ischaemia

  2009influential reference
• Distribution and biological activities of the flavonoid luteolin.

  2009influential reference
• Luteolin as a therapeutic option for multiple sclerosis

  2009cited by this paper
• An emerging role of mast cells in cerebral ischemia and hemorrhage

  2009cited by this paper
• Luteolin, a flavonoid with potential for cancer prevention and therapy.

  2008cited by this paper
• Mast cells in the promotion and limitation of chronic inflammation

  2007influential reference
• The Multitasking Mast Cell: Positive and Negative Roles in the Progression of Autoimmunity

  2007cited by this paper
• Cerebral Mast Cells Regulate Early Ischemic Brain Swelling and Neutrophil Accumulation

  2006cited by this paper
• Rapid Broad-Spectrum Analgesia through Activation of Peroxisome Proliferator-Activated Receptor-α

  2006cited by this paper
• Mast cells in the development of adaptive immune responses

  2005influential reference
• Effect of oxygen–glucose deprivation on degranulation and histamine release of mast cells

  2005influential reference
• Effect of cerebral ischemia on brain mast cells in rats.

  2004cited by this paper
• Mast-cell responses to pathogens

  2004cited by this paper
• Neuroprotection by flavonoids.

  2003cited by this paper
• Mast Cells Migrate from Blood to Brain

  2000cited by this paper
• The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons.

  1996cited by this paper
• Mast Cell Activation Causes Delayed Neurodegeneration in Mixed Hippocampal Cultures via the Nitric Oxide Pathway

  1996cited by this paper
• Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide.

  1995cited by this paper
• Mast cells: the immune gate to the brain.

  1990cited by this paper
• Histamine release from rat mast cells induced by metabolic activation of polyunsaturated fatty acids into free radicals.

  1990cited by this paper
• Eosinophil peroxidase-induced mast cell secretion

  1980cited by this paper
• Mast cells in the human brain.

  1979cited by this paper

• PEALut in the Dietary Management of Patients with Acute Ischemic Stroke: A Prospective Randomized Controlled Clinical Trial

  2024cites this paper
• Luteolin for neurodegenerative diseases: a review

  2024cites this paper
• Tackling persistent neurological symptoms in patients following acute COVID-19 infection: an update of the literature

  2024cites this paper
• Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review.

  2024cites this paper
• Treatment of COVID-19 olfactory dysfunction with olfactory training, palmitoylethanolamide with luteolin, or combined therapy: a blinded controlled multicenter randomized trial

  2023cites this paper
• Bioactive compounds from Actinidia arguta fruit as a new strategy to fight glioblastoma.

  2023cites this paper
• Thromboinflammation in Brain Ischemia: Recent Updates and Future Perspectives

  2022cites this paper
• Plant based food bioactives: A boon or bane for neurological disorders

  2022cites this paper
• Therapeutic Strategies for Immune Transformation in Parkinson’s Disease

  2022cites this paper
• Overview of the Endocannabinoid System and Endocannabinoidome

  2022cites this paper
• Role of luteolin in overcoming Parkinson's disease

  2021cites this paper
• LUTEOLIN AND HORMESIS.

  2021cites this paper
• Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention

  2021cites this paper
• From Preclinical Stroke Models to Humans: Polyphenols in the Prevention and Treatment of Stroke

  2020cites this paper
• Looking for a Treatment for the Early Stage of Alzheimer’s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin

  2020cites this paper
• Neuroprotective Properties of Cannabinoids in Cellular and Animal Models: Hypotheses and Facts

  2020cites this paper
• Luteolin protects PC-12 cells from H2O2-induced injury by up-regulation of microRNA-21.

  2019cites this paper
• Targeting mast cell as a neuroprotective strategy

  2019cites this paper
• A Polyphenol-Enriched Supplement Exerts Potent Epigenetic-Protective Activity in a Cell-Based Model of Brain Ischemia

  2019cites this paper
• Phytochemistry and neuroprotective effects of Eclipta alba (L.) Hassk

  2019cites this paper
• The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

  2019cites this paper
• The Role of Mast Cells in Stroke

  2019influential citation
• Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia

  2018cites this paper
• Vascular dementia and aliamides: A new approach for the future

  2018cites this paper
• Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies.

  2018cites this paper
• Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon.

  2017cites this paper
• Topically Applied Nicotinamide Inhibits Human Hair Follicle Growth Ex Vivo.

  2017cites this paper